PRIMALS - A Precision Medicine Biomarkers Study in ALS, Based on Pathology-Relevant Signals
Grant Amount: NIS 3.6 million
About the Project
PRIMALS is a robust precision medicine program to promote neurodegeneration patho-mechanisms and boost clinical research. PRIMALS endpoints are the discovery and substantiated validation of precision biomarkers for amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). The program builds on research in human models of disease based on stem cell and then in human patient blood samples. The researchers expect disease-specific results and conceptual breakthroughs that can be extended to other pathologies.
Research Team
Prof. Arie Admon
Biology, Technion-Israel Institute of Technology
Prof. Vivian Drory
Neurology, Sourasky Medical Center
Prof. Eran Hornstein
Molecular Neurobiology and Molecular Genetics, Weizmann Institute of Science
Prof. Eran Perlson
Physiology and Pharmacology, Tel Aviv University
More Projects Funded